HOME
ABOUT US
SERVICES
ACCESS
FIND A DOCTOR
CLINICAL RESEARCH
CLINICAL TRIAL
CONTACT
More
Cannabidiol Attenuates Cisplatin-Induced Nephrotoxicity by Decreasing Oxidative/Nitrosative Stress, Inflammation, and Cell Death
Cannabidiol Rescues Acute Hepatic Toxicity and Seizure Induced by Cocaine
Cannabinoid effects on ventilation and breathlessness: A pilot study of efficacy and safety
Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up
Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS)
CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity
Comparison of Cannabidiol, Antioxidants, and Diuretics in Reversing Binge Ethanol-Induced Neurotoxicity
Δ9-Tetrahydrocannabinol Prevents Methamphetamine-Induced Neurotoxicity
Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study
Endocannabinoid signaling in neurotoxicity and neuroprotection
Molecular Mechanisms of Cannabinoid Protection from Neuronal Excitotoxicity
Neuroprotection by Δ9-Tetrahydrocannabinol, the Main Active Compound in Marijuana, against Ouabain-Induced In Vivo Excitotoxicity
Neuroprotective and Blood-Retinal Barrier-Preserving Effects of Cannabidiol in Experimental Diabetes
Neuroprotective Effect of(−)Δ9-Tetrahydrocannabinol and Cannabidiol in N-Methyl-d-Aspartate-Induced Retinal Neurotoxicity
Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on b-amyloid-induced toxicity in PC12 cells
Nonpsychoactive Cannabidiol Prevents Prion Accumulation and Protects Neurons against Prion Toxicity
Potentiation of Cannabinoid-Induced Cytotoxicity in Mantle Cell Lymphoma through Modulation of Ceramide Metabolism
Protective effect of cannabidiol against cadmium hepatotoxicity in rats
Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma
Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent
Safety and Toxicology of Cannabinoids
A clinical comparison of schizophrenia with and without pre-onset cannabis use disorder: a retrospective cohort study using categorical and dimensional approaches
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Cannabidiol Reverses MK-801-Induced Disruption of Prepulse Inhibition in Mice
Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain
Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis
Cannabis use in sickle cell disease: a questionnaire study
Pain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: modulation by cannabinoids
Activation of Cannabinoid Receptor 2 Enhances Osteogenic Differentiation of Bone Marrow Derived Mesenchymal Stem Cells
Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes
Cannabinoid receptors and the regulation of bone mass
Cannabinoids and bone: endocannabinoids modulate human osteoclast function in vitro
Cannabinoids and the skeleton: From marijuana to reversal of bone loss
Effects of deleting cannabinoid receptor-2 on mechanical and material properties of cortical and trabecular bone
Peripheral cannabinoid receptor, CB2, regulates bone mass
Protective Effects of Cannabidiol on Lesion-Induced Intervertebral Disc Degeneration
Role of cannabinoids in the regulation of bone remodeling
The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling
The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities
The Role of Type 2 Cannabinoid Receptor in Bone Metabolism
Cannabidiol Application Increases Cutaneous Aquaporin-3 and Exerts a Skin Moisturizing Effect.
Cannabinoids for skin diseases and hair regrowth.
The potential role of cannabinoids in dermatology.
Therapeutic Potential of Cannabidiol (CBD) for Skin Health and Disorders.
Administration of URB597, Oleoylethanolamide or Palmitoylethanolamide Increases Waking and Dopamine in Rats
A Longitudinal Study of Prenatal Marijuana Use
A Pilot Study into the Effects of the CB1 Cannabinoid Receptor Agonist WIN55,212-2 or the Antagonist/Inverse Agonist AM251 on Sleep in Rats
Around‐the‐Clock Oral THC Effects on Sleep in Male Chronic Daily Cannabis Smokers
Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis
Cannabidiol in Anxiety and Sleep: A Large Case Series
(−)δ9 THC as an hypnotic
Effect of cannabis and certain of its constituents on pentobarbitone sleeping time and phenazone metabolism
Effect of Δ-9-Tetrahydrocannabinol and Cannabidiol on Nocturnal Sleep and Early-Morning Behavior in Young Adults
Effect of illicit recreational drugs upon sleep: Cocaine, ecstasy and marijuana
Endocannabinoid Signaling Regulates Sleep Stability
Functional Role for Cannabinoids in Respiratory Stability During Sleep
Intrahippocampal administration of anandamide increases REM sleep
Intranodose ganglion injections of dronabinol attenuate serotonin-induced apnea in Sprague-Dawley rat
Modulation of Sleep-Wake Cycles in Mice and Rats with Cannabinoids
Potential Effects of Cannabidiol as a Wake-Promoting Agent
Proof of concept trial of dronabinol in obstructive sleep apnea
The effects of cannabinoid administration on sleep: a systematic review of human studies
The Emerging Role of the Endocannabinoid System in the Sleep-Wake Cycle Modulation
The Nonpsychoactive Cannabis Constituent Cannabidiol Is a Wake-Inducing Agent
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial
Cannabinoids in the management of spasticity associated with multiple sclerosis
Clinical experiences with cannabinoids in spasticity management in multiple sclerosis
Sativex in the Management of Multiple Sclerosis-Related Spasticity: Role of the Corticospinal Modulation
Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial
Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity
Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review
Activation of Cannabinoid CB2 Receptor–Mediated AMPK/CREB Pathway Reduces Cerebral Ischemic Injury
Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion
Acute upregulation of neuronal mitochondrial type-1 cannabinoid receptor and it’s role in metabolic defects and neuronal apoptosis after TBI
An endogenous cannabinoid (2-AG) is neuroprotective after brain injury
Cannabidiol administration after hypoxia–ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function
Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury
Cannabidiol treated rats exhibited higher motor score after cryogenic spinal cord injury.
Cannabinoid agonist rescues learning and memory after a traumatic brain injury
Cannabinoid CB2 Receptor Activation Attenuates Motor and Autonomic Function Deficits in a Mouse Model of Spinal Cord Injury
Cannabis Responsive Head Injury Induced Mutiple Disabilities: A Case Report
CB1 and CB2 Cannabinoid Receptor Antagonists Prevent Minocycline-Induced Neuroprotection Following Traumatic Brain Injury in Mice
Early increase of cannabinoid receptor density after experimental traumatic brain injury in the newborn piglet
Effects of Cannabidiol and Hypothermia on Short-Term Brain Damage in New-Born Piglets after Acute Hypoxia-Ischemia
Endocannabinoids and traumatic brain injury
Estradiol Decreases Cortical Reactive Astrogliosis after Brain Injury by a Mechanism Involving Cannabinoid Receptors
HU211, a Novel Noncompetitive NMethylDAspartate Antagonist, Improves Neurological Deficit and Reduces Infarct Volume After Reversible Focal Cerebral Ischemia in the Rat
Injury, Pain, and Prescription Opioid Use Among Former National Football League (NFL) Players*
Mechanisms of cannabidiol neuroprotection in hypoxiceischemic newborn pigs: Role of 5HT1A and CB2 receptors
Tissue Engineering of Cartilage; Can Cannabinoids Help?
The Cannabinoid Agonist Win55212 Reduces Brain Damage in an In Vivo Model of Hypoxic-Ischemic Encephalopathy in Newborn Rats
The endocannabinoid 2-AG protects the blood–brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines
Therapeutic potential of cannabidiol against ischemia/reperfusion liver injury in rats
Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke
Update on the Role of Cannabinoid Receptors after Ischemic Stroke
Cannabinoids in experimental stroke: a systematic review and meta-analysis
